This PhD is part funded through the Knowledge and Economy Skills Scholarship 2 Programme which you can find out more about here
Prostate cancer is the second major cause of cancer-related deaths in men, accounting for over 300,000 deaths per year worldwide. Despite high response rates to androgen deprivation therapy (ADT) in advanced prostate cancer patients, nearly all eventually develop progressive, castrate-resistant prostate cancer (CRPC). The main treatment for CRPC is chemotherapy or ADT, yet survival is very poor, emphasising the urgent clinical need to identify novel therapeutic strategies to treat Prostate cancer and castrate-resistant prostate cancer.
This PhD project aims to establish the cooperating genetic events underpinning accelerated CRPC progression, to develop a new ex-vivo (samples tested outside of an organism) platform for prostate cancer preclinical trials, and to identify/test novel therapeutic targets and diagnostic biomarkers.
Ultimately, this work will provide critical insights into targeting the specific pathway in prostate cancer patients, and has immediate implications for the design of clinical trials.